Logo image of OCEA

OCEAN BIOMEDICAL INC (OCEA) Stock Fundamental Analysis

NASDAQ:OCEA - Nasdaq - US67644C1045 - Common Stock - Currency: USD

0.0205  -0.02 (-46.75%)

After market: 0.02 0 (-2.44%)

Fundamental Rating

0

OCEA gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. OCEA has a bad profitability rating. Also its financial health evaluation is rather negative. OCEA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OCEA had negative earnings in the past year.
In the past year OCEA has reported a negative cash flow from operations.
OCEA Yearly Net Income VS EBIT VS OCF VS FCFOCEA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -1051.00%, OCEA is doing worse than 98.41% of the companies in the same industry.
Industry RankSector Rank
ROA -1051%
ROE N/A
ROIC N/A
ROA(3y)-1044.23%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OCEA Yearly ROA, ROE, ROICOCEA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

OCEA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCEA Yearly Profit, Operating, Gross MarginsOCEA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, OCEA has more shares outstanding
Compared to 1 year ago, OCEA has a worse debt to assets ratio.
OCEA Yearly Shares OutstandingOCEA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
OCEA Yearly Total Debt VS Total AssetsOCEA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -376.89, we must say that OCEA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -376.89, OCEA is doing worse than 98.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -376.89
ROIC/WACCN/A
WACCN/A
OCEA Yearly LT Debt VS Equity VS FCFOCEA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 0.02 indicates that OCEA may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.02, OCEA is doing worse than 98.59% of the companies in the same industry.
OCEA has a Quick Ratio of 0.02. This is a bad value and indicates that OCEA is not financially healthy enough and could expect problems in meeting its short term obligations.
OCEA has a Quick ratio of 0.02. This is amonst the worse of the industry: OCEA underperforms 98.59% of its industry peers.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
OCEA Yearly Current Assets VS Current LiabilitesOCEA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.24% over the past year.
EPS 1Y (TTM)90.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OCEA Yearly EPS VS EstimatesOCEA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OCEA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCEA Price Earnings VS Forward Price EarningsOCEA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCEA Per share dataOCEA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

OCEA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCEAN BIOMEDICAL INC

NASDAQ:OCEA (4/23/2025, 8:26:33 PM)

After market: 0.02 0 (-2.44%)

0.0205

-0.02 (-46.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-08 2025-04-08
Earnings (Next)N/A N/A
Inst Owners2.83%
Inst Owner Change26.21%
Ins Owners0.06%
Ins Owner Change0%
Market Cap3.40M
Analysts82.86
Price TargetN/A
Short Float %0.19%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0
BVpS-0.59
TBVpS-0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1051%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1044.23%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -376.89
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.65%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y61.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-133.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.67%
OCF growth 3YN/A
OCF growth 5YN/A